Lymphoma is a blood cancer which occurs if white blood cells of the immune system, grow and multiply uncontrollably. Twenty percent of all lymphoma patients are diagnosed with Hodgkin lymphoma. The disease usually occurs in individuals either aged between 20 to 25 or over 75 years. Symptoms include swelling of lymph nodes in the neck, armpit or groin, recurring fever, night sweats, weight loss, cough, breathlessness, abdominal pain and itching. There is an unmet need for novel strategies to improve survival rates.
Brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for previously untreated late-stage classical Hodgkin lymphoma
Lymphoma is a blood cancer which occurs if white blood cells of the immune system, grow and multiply uncontrollably. Twenty percent of all lymphoma patients are diagnosed with Hodgkin lymphoma.
Interventions:
Brentuximab vedotin (Adcetris; SGN-35)
, Dacarbazine (dacarbazine citrate)
, Doxorubicin (Livatag; BA-003; Caelyx; Sarcodoxome; SP-1049C; Resmycin; JNS002; doxorubicin hydrochloride)
, Vinblastine (vinblastine sulfate)
Indications:
Hodgkin lymphoma
Therapeutic Areas:
Haematological Cancer and Lymphomas
Year:
2023